Quantum-Si Appoints Former Bio-Techne President and CEO, Chuck Kummeth, to serve as independent Chairman of the Board of Directors
31 5월 2024 - 5:05AM
Business Wire
Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or
the “Company”), The Protein Sequencing Company™, today announced
the appointment of Charles (“Chuck”) Kummeth to the role of
independent Chairman of the Board, effective May 27, 2024.
Mr. Kummeth has over 35 years of leadership experience in Life
Sciences most recently as President and CEO of Bio-Techne. During
Mr. Kummeth’s tenure at Bio-Techne, he oversaw tremendous growth
across all aspects of the business including annual revenue growth
from $300M to over $1.1B, growth in the employee base from 800 to
over 3,000, and the successful execution of 19 acquisitions, all
while maintaining a 35% or better EBITDA level. Under Mr. Kummeth’s
leadership, Bio-Techne’s market capitalization grew from $2.2B to a
high of $21B, culminating in an invitation for the company to join
the S&P 500.
Prior to Bio-Techne, Mr. Kummeth served as President of Mass
Spectrometry and Chromatography and President of the Laboratory
Consumables Division at Thermo Fisher Scientific Inc. Prior to
joining Thermo Fisher, Mr. Kummeth served in various roles during
his 24-year career at 3M Corporation, culminating as the Vice
President of the company's Medical Division.
“We are thrilled to welcome Chuck as the independent Chairman of
the Board of Directors,” said Jeff Hawkins, President and Chief
Executive Officer of Quantum-Si. “Chuck’s broad operational
experience in the Life Sciences industry in general and the field
of proteomics specifically, combined with his proven public company
leadership track record, will be an invaluable asset to Quantum-Si
as the company continues to expand its reach and impact in
proteomics.”
Dr. Jonathan Rothberg, who has served as Chairman of the Board
since our inception, will remain a member of the Board of Directors
of the Company going forward. “I am excited for Chuck to step in to
the role of Chairman of the Board and believe his deep experience
in the field will help deliver on the founding vision for
Quantum-Si, to enable customers to make scientific breakthroughs
that will ultimately improve the lives of the people we love,” said
Dr. Rothberg.
“I am honored to join Quantum-Si as the Chairman of the Board of
Directors,” said Mr. Kummeth. “I believe Quantum-Si’s technology
has the potential to transform the field of proteomics initially in
research and drug development and longer term, expanding into
clinical diagnostics. I look forward to leading the Board of
Directors and helping to guide the Company through this next phase
of growth and value creation.”
Mr. Kummeth received a BS in Electrical Engineering from the
University of North Dakota, and a MS in Computer Science from the
University of St. Thomas and an MBS from the Carlson School of
Business at the University of Minnesota. Mr. Kummeth also serves on
the boards of Gentherm, a thermal management technology company,
PerkinElmer, a life sciences company, and Orthofix, a global spine
and orthopedics company.
About Quantum-Si Incorporated
Quantum-Si, The Protein Sequencing Company™, is focused on
revolutionizing the growing field of proteomics. The Company’s
suite of technologies is powered by a first-of-its-kind
semiconductor chip designed to enable next-generation
single-molecule protein sequencing and digitize proteomic research
in order to advance drug discovery and diagnostics beyond what has
been possible with DNA sequencing. Learn more at quantum-si.com or
follow us on LinkedIn or X.
Forward Looking Statements
This press release includes "forward-looking statements" within
the meaning of the "safe harbor" provisions of the United States
Private Securities Litigation Reform Act of 1995. The actual
results of the Company may differ from its expectations, estimates,
and projections and, consequently, you should not rely on these
forward-looking statements as predictions of future events. Words
such as "expect," "estimate," "project," "budget," "forecast,"
"anticipate," "intend," "plan," "may," "will," "could," "should,"
"believes," "predicts," "potential," "continue," and similar
expressions (or the negative versions of such words or expressions)
are intended to identify such forward-looking statements. These
forward-looking statements include, without limitation, the
Company's expectations with respect to future performance and
development and commercialization of products and services. These
forward-looking statements involve significant risks and
uncertainties that could cause the actual results to differ
materially from those discussed in the forward-looking statements.
Most of these factors are outside the Company's control and are
difficult to predict. Factors that may cause such differences
include, but are not limited to: the inability to maintain the
listing of the Company's Class A common stock on The Nasdaq Stock
Market; the ability of the Company to grow and manage growth
profitably and retain its key employees; the Company’s ongoing
leadership transitions; changes in applicable laws or regulations;
the ability of the Company to raise financing in the future; the
success, cost and timing of the Company's product development and
commercialization activities; the commercialization and adoption of
the Company’s existing products and the success of any product the
Company may offer in the future; the potential attributes and
benefits of the Company’s commercialized Platinum® protein
sequencing instrument and kits and the Company’s other products
once commercialized; the Company's ability to obtain and maintain
regulatory approval for its products, and any related restrictions
and limitations of any approved product; the Company's ability to
identify, in-license or acquire additional technology; the
Company's ability to maintain its existing lease, license,
manufacture and supply agreements; the Company's ability to compete
with other companies currently marketing or engaged in the
development or commercialization of products and services that
serve customers engaged in proteomic analysis, many of which have
greater financial and marketing resources than the Company; the
size and growth potential of the markets for the Company's products
and services, and its ability to serve those markets once
commercialized, either alone or in partnership with others; the
Company's estimates regarding future expenses, future revenue,
capital requirements and needs for additional financing; the
Company's financial performance; and other risks and uncertainties
described under "Risk Factors" in the Company’s most recent Annual
Report on Form 10-K and Quarterly Report on Form 10-Q, and in the
Company's other filings with the SEC. The Company cautions that the
foregoing list of factors is not exclusive. The Company cautions
readers not to place undue reliance upon any forward-looking
statements, which speak only as of the date made. The Company does
not undertake or accept any obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements
to reflect any change in its expectations or any change in events,
conditions, or circumstances on which any such statement is
based.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240530200214/en/
Investor Contact Jeff Keyes, Chief Financial Officer
ir@quantum-si.com
Media Contact Katherine Atkinson, SVP, Commercial
Marketing media@quantum-si.com
Quantum Si (NASDAQ:QSI)
과거 데이터 주식 차트
부터 8월(8) 2024 으로 9월(9) 2024
Quantum Si (NASDAQ:QSI)
과거 데이터 주식 차트
부터 9월(9) 2023 으로 9월(9) 2024